Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients

European Journal of Clinical Pharmacology

Volumn 64, Issue 5, 2008, Pages 489-495

  Ferrari, Anna ^a   Pinetti, Diego ^a   Bertolini, Alfio ^a   Coccia, Ciro ^a   Sternieri, Emilio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Absorption; Pharmacokinetics; Response; Sumatriptan; Variability

Indexed keywords

SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN SUCCINATE; TRIPTAN DERIVATIVE;

ADULT; ARTERIAL PRESSURE; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HEADACHE; HEART RATE; HUMAN; INJECTION SITE BURNING; MALE; MIGRAINE; NAUSEA; PATIENT SATISFACTION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT INDICATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MIGRAINE WITHOUT AURA; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 41049085957     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0443-9     Document Type: Article

References (44)

1. Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine-current understanding and treatment. N Engl J Med 346(4):257-270
2. Dodick DW (2005) Triptan nonresponder studies: implications for clinical practice. Headache 45(2):156-162
3. Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352(21):2211-2221
4. Freidank-Mueschenborn E, Fox AW (2005) Resolution of concentration- response differences in onset of effect between subcutaneous and oral sumatriptan. Headache 45(6):632-637
5. Fowler PA, Thomas M, Lacey LF, Andrew P, Dallas FA (1989) Early studies with the novel 5-HT 1-like agonist GR43175 in healthy volunteers. Cephalalgia 9(Suppl 9):57-62
6. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS (1991) The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 31(5):291-294
7. Scott AK (1994) Sumatriptan clinical pharmacokinetics. Clin Pharmacokinet 27(5):337-344
8. Lacey LF, Hussey EK, Fowler PA (1995) Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 47(6):543-548
9. Duquesnoy C, Mamet JP, Sumner D, Fuseau E (1998) Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci 6(2):99-104
10. Fox AW (2004) Onset of effect of 5-HT1B/1D agonists: a model with pharmacokinetic validation. Headache 44(2):142-147
11. Ahn AH, Basbaum AI (2005) Where do triptans act in the treatment of migraine? Pain 115(1-2):1-4
12. Burstein R, Jakubowski M (2005) Implications of multimechanism therapy: when to treat. Neurology 64(10 Suppl 2):S16-S20
13. Burstein R, Jakubowski M, Collins B (2004) Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 55(1):19-26
14. Cady R, Martin V, Mauskop A, Rodgers A, Hustad C, Ramsey K, Skobieranda F (2007) Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. Cephalalgia 27(9):1055-1060
15. D'Amico D, Moschiano F, Bussone G (2006) Early treatment of migraine attacks with triptans: a strategy to enhance outcomes and patient satisfaction? Expert Rev Neurother 6(7):1087-1097
16. Goadsby PJ (2005) Migraine, allodynia, sensitization and all of that. Eur Neurol 53(Suppl 1):10-16
17. Landy SH, McGinnis JE, McDonald SA (2007) Clarification of developing and established clinical allodynia and pain-free outcomes. Headache 47(2):247-252
18. Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD (2003) The triptan formulations : how to match patients and products. CNS Drugs 17(6):431-447
19. Walls C, Lewis A, Bullman J, Boswell D, Summers SJ, Dow A, Sidhu J (2004) Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Curr Med Res Opin 20(6):803-809
20. Headache Classification Subcommittee of the International Headache Society (2004) The international classification of headache disorders, 2nd edn. Cephalalgia 24(Suppl 1):S9-S160
21. Ferrari A, Sternieri E, Ferraris E, Bertolini A (2003) Emerging problems in the pharmacology of migraine: interactions between triptans and drugs for prophylaxis. Pharmacol Res 48(1):1-9
22. Dunne M, Andrew P (1996) Fully automated assay for the determination of sumatriptan in human serum using solid-phase extraction and high-performance liquid chromatography with electrochemical detection. J Pharm Biomed Anal 14(6):721-726
23. Lacey LF, Keene ON, Duquesnoy C, Bye A (1994) Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies. J Pharm Sci 83(2):212-215
24. Normann G, Streiner D (2000) Biostatistics. The bare essentials, 2nd edn. B.C. Decker Inc., Ontario, Canada, pp 1-162
25. Plosker GL, McTawish D (1994) Sumatriptan: a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 47(4):622-651
26. Dahlof CG (2001) Sumatriptan: pharmacological basis and clinical results. Curr Med Res Opin 17(Suppl 1):s35-s45
27. Carpay J, Schoenen J, Ahmad F, Kinrade F, Boswell D (2004) Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin Ther 26(2):214-223
28. Barbanti P, Le Pera D, Cruccu G (2007) Sumatriptan fast-disintegrating/ rapid-release tablets in the acute treatment of migraine. Expert Rev Neurother 7(8):927-934
29. Sheftell FD, Dahlof CG, Brandes JL, Agosti R, Jones MW, Barrett PS (2005) Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Clin Ther 27(4):407-417
30. Cady RK, Sheftell F, Lipton RB, O'Quinn S, Jones M, Putnam DG, Crisp A, Metz A, McNeal S (2000) Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther 22(9):1035-1048
31. Linde M, Mellberg A, Dahlof C (2006) Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. Cephalalgia 26(2):113-121
32. Geraud G, Keywood C, Senard JM (2003) Headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 43(4):376-388
33. Maas HJ, Danhof M, Della Pasqua OE (2006) Prediction of headache response in migraine treatment. Cephalalgia 26(4):416-422
34. Visser WH, Burggraaf J, Muller LM, Schoemaker RC, Fowler PA, Cohen AF, Ferrari MD (1996) Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharmacol Ther 60(4):452-460
35. Sternieri E, Pinetti D, Coccia CP, Leone S, Bertolini A, Ferrari A (2005) Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients. J Headache Pain 6(4):319-321
36. Visser WH, de Vriend RH, Jaspers NH, Ferrari MD (1996) Sumatriptan non responders: a survey in 366 migraine patients. 36(8):471-475
37. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr (1991) Treatment of acute migraine with subcutaneous sumatriptan. JAMA 265(21):2831-2835
38. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358(9294):1668-1675
39. Tfelt-Hansen P, De Vries P, Saxena PR (2000) Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60(6):1259-1287
40. Winner P, Adelman J, Aurora S, Lener ME, Ames M (2006) Efficacy and tolerability of sumatriptan injection for the treatment of morning migraine: two multicenter, prospective, randomized, double-blind, controlled studies in adults. Clin Ther 28(10):1582-1591
41. Dahlöf CG, Lipton RB, McCarroll KA, Kramer MS, Lines CR, Ferrari MD (2000) Within-patient consistency of response of rizatriptan for treating migraine. Neurology 55(10):1511-1516
42. Tfelt-Hansen P (2007) Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. A comment. J Headache Pain 8(5):273-276, Online DOI 10.1007/s10194-007-0411-x
43. The Oral Sumatriptan Dose-Defining Study Group (1991) Sumatriptan-an oral dose-defining study. Eur Neurol 31(5):300-305
44. Cutler NR, Hussey EK, Sramek JJ, Clements BD, Paulsgrove LA, Busch MA, Donn KH (1991) Oral sumatriptan in pharmacokinetics in the migranous state. Cephalalgia 11(Suppl 11):222-223